PATENT CLAIM ANALYSIS

Application Number: 16183933
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "221000"]

Abstract:
Methods of treating behavioral syndromes by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat Attention-Deficit Disorder (ADD) and Attention-Deficit Hyperactivity Disorder (ADHD).

Claim (Index 4):
The method of  claim 1  further comprising administering a compound selected from the group consisting of gaboxadol, acetazolamide, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, leviteracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.20588
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15604776', '14876110', '15493374', '15191068', '15155625']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7320714930713591
- 35 USC 102 Novelty (BERT): 0.4741388913116422
- Combined Prediction Score: 0.7062782328953874
- Mean Citation Score: 192.821926
- Max Citation Score: 228.4165
- Similarity Product: 217.4465906225145

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test